Body Handbook Catalogue Profile Ranking
Screening BODY HANDBOOK
Screening ยท ยง100
Ashkenazi Jewish Carrier Screening
If even one grandparent was Ashkenazi Jewish and kids are on your horizon, this is a saliva sample you mail in before you start trying. It surfaces the recessive alleles that ran through that gene pool โ€” Tay-Sachs, Canavan, Gaucher, a dozen more. Here's what you didn't know you didn't know: the same panel catches the three BRCA cancer mutations that rode along, carried by about 1 in 40 of these adults. Take it before conception and every option stays open. About a hundred dollars.
Screen ยท Once Evidence Strong Chapter Screening

You are probably a silent carrier. Roughly two in three Ashkenazi adults carry at least one disease allele and never know it 1. The risk only lands when both partners carry the same broken gene, about 1 couple in 100 to 300, and then each pregnancy has a 25% chance of an affected child.

The screen works. Tay-Sachs in North American Ashkenazi populations dropped about 90% after testing began, from roughly 50 affected babies a year to fewer than five 2. Every major guideline body offers it to people of Ashkenazi ancestry 3.

The BRCA piggyback is the part nobody mentions. About 1 in 40 Ashkenazi adults carries a founder mutation in BRCA1 or BRCA2, and the same panel surfaces it 4. A BRCA1 carrier has roughly a 57% lifetime breast-cancer risk and 40% ovarian-cancer risk 5. Most carriers have no family history that would ever trigger testing the usual way 6.

Test one partner first. The disease takes two carriers, so a single negative closes the question and halves the cost. No reason to test both up front.

Start at least three months before you want to start trying 3.

Most readers get a negative, and the question just closes. The background "I hope it's fine" of trying to conceive becomes a number you stop worrying about.

For a carrier couple, preimplantation embryo testing drops the per-pregnancy risk from 25% to essentially zero by only transferring unaffected embryos 7. More than 90% of at-risk couples in the Mt. Sinai cohort took some path 1.

For the 1 in 40 who carry BRCA, surveillance starts in the twenties and a risk-reducing surgery conversation comes in the thirties. Carriers who follow that pathway show about a 77% reduction in all-cause mortality 8. That's the difference between finding stage III ovarian cancer at 52 and having it removed at 38.

The fine print โ€” when to skip it, and what people get wrong

What people get wrong. Family history is not a useful signal here; most at-risk couples have none 6. One Ashkenazi grandparent is enough to test 3. Secular and observant adults carry at the same rates. A negative catches ~98% of Ashkenazi alleles, not every genetic condition.

The one real caution. The BRCA module is cancer-risk information about you, not your future child โ€” a positive means surveillance and a surgery discussion for life 9. Most labs let you opt out if you want only the reproductive result.

The avoidable screwups. Testing after conception, which kills the calmer options. The partner who never gets around to the reflex test. Running an Ashkenazi-only panel on a mixed-ancestry couple; use the expanded pan-ethnic panel. Finding a BRCA mutation and doing nothing about it 8.

References
  1. 1Scott SA, Edelmann L, Liu L et al. (2010). Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Human Mutation. link
  2. 2Kaback MM (2000). Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. European Journal of Pediatrics. link
  3. 3ACOG (2017). Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstetrics & Gynecology. link
  4. 4Gross SJ, Pletcher BA, Monaghan KG (2008). Carrier screening in individuals of Ashkenazi Jewish descent. Genetics in Medicine. link
  5. 5King MC, Marks JH, Mandell JB (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. link
  6. 6Manchanda R, Loggenberg K, Sanderson S et al. (2015). Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. Journal of the National Cancer Institute. link
  7. 7Metcalfe SA (2018). Carrier screening in preconception consultation in primary care. Journal of Community Genetics. link
  8. 8Domchek SM, Friebel TM, Singer CF et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. link
  9. 9NCCN (2024). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. link
Related in the handbook (2)
Related
  • โ€” Ashkenazi Jewish ancestry carries founder BRCA mutations โ€” a reason to consider this test specifically.
  • โ€” This is the targeted, do-it-before-pregnancy kind of genetic testing โ€” not a spit-kit ancestry report.
ยท
100